Results 131 to 140 of about 198,039 (308)

Neoadjuvant Chemotherapy With Gemcitabine/Cisplatin/S‐1 for Resectable Biliary Tract Cancer With FDG‐PET‐Positive Lymph Node Metastasis (KHBO1201): A Multicenter Phase II Trial

Journal of Hepato-Biliary-Pancreatic Sciences, EarlyView.
ABSTRACT Purpose To evaluate the safety and efficacy of neoadjuvant gemcitabine, cisplatin, and S‐1 (GCS) chemotherapy for resectable biliary tract cancer (BTC) and FDG‐PET‐positive lymph nodes in a multicenter phase II study (KHBO1201). Methods Patients with resectable BTC (intrahepatic/extrahepatic bile duct, gallbladder, or ampullary cancers) and ...
Satoshi Ogiso, Etsuro Hatano, Satoru Seo, Masashi Kanai, Shogo Kobayashi, Hiroshi Wada, Hidetoshi Eguchi, Tatsuya Higashi, Hiroaki Nagano, Tatsuya Ioka   +9 more
wiley   +1 more source

A case of severe visual loss related to treatment with pembrolizumab for metastatic renal pelvic cancer

IJU Case Reports
Introduction Pembrolizumab is the standard therapy for urothelial carcinoma treatment; however, adverse events have been noted. Here, we report a rare case of vision loss as an immune‐related adverse event of pembrolizumab therapy in a patient with ...
Naoki Inoue, Mihoko Iitzuka, Hiroki Tanaka, Yudai Ishikawa, Naoko Kawamura, Tetsuo Okuno   +5 more
doaj   +1 more source

Spatial comparison of molecular features associated with resistance to pembrolizumab in BCG unresponsive bladder cancer

Journal for ImmunoTherapy of Cancer
Intravenous immune checkpoint inhibition achieves a 40% 3-month response in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ.
Joshua J Meeks, Khyati Meghani, Noah Frydenlund, Yanni Yu, Bonnie Choy   +4 more
doaj   +1 more source

Metastatic small cell bladder cancer treated with sequential systemic therapy including pembrolizumab and amrubicin: A case report [PDF]

, 2023
Kazutaka Mitani, Ichiro Tsuboi, Gen Tanaka, Saori Yosioka, Shuhei Yokoyama, Yusuke Kobayashi, Hirochika Nakajima, Taichi Nagami, Kohei Ogawa, Koichiro Wada   +9 more
openalex   +1 more source

Changing Practices in Axillary Surgery After Neoadjuvant Breast Cancer Therapy: Insights From the EUSOMA European Database

Journal of Surgical Oncology, EarlyView.
ABSTRACT Introduction Sentinel lymph node biopsy (SLNB) after neoadjuvant treatment (NAT) is an increasing option for axillary surgery in patients responding to treatment, whether diagnosed as clinically node‐negative (cN0) or node‐positive (cN + ). This study evaluates SLNB trends in patients with NAT in a large European population.
Antonio J. Esgueva, Mariano Tomatis, Antonio Ponti, Lorenza Marotti, Maria Joao Cardoso, Kwok Leung Cheung, Jakob De Vries, Peter van Dam, Isabel T. Rubio, The Eusoma Working group, Chiara Annunziata Pasqualina Anghelone, Antonella Baldissera, Elisabetta Benozzi, Martine Berlière, Marina Bortul, Barbara Bussels, Francesco Caruso, Carla Cedolini, Fabio Corsi, Evelyn Despierre, Boudewijn Dullens, Gianluca Fogazzi, Lucio Fortunato, José Luis Fougo, Gianluca Frisoni, Daniele Generali, Alessandra Gennari, Matteo Ghilli, Marco Golinelli, Pedro Gouveia, Simona Grossi, Ruth Helfgott, Alessandra Huscher, Karolina F. Larsson, Sophie Marquette, Carmela Mocerino, Ida Negreiros, Francesca Pellini, Federico Piacentini, Romano Polato, Annemie Prové, Karol Rogowski, Giovanna Romanucci, Lorenzo Rossi, Claudia Francesca Rossi, Margherita Serra, Gracienne Staelens, Maud Vassilieff, Paolo Veronesi, Daniele Zanoni   +49 more
wiley   +1 more source

Paraneoplastic Florid Oral Papillomatosis and Malignant Acanthosis Nigricans Associated With HPV‐Related Squamous Cell Carcinoma of Unknown Primary

JEADV Clinical Practice, EarlyView.
ABSTRACT We present the case of a 76‐year‐old man with paraneoplastic florid oral papillomatosis (FOP) and malignant acanthosis nigricans (MAN) associated with an HPV‐16‐positive keratinizing squamous cell carcinoma of unknown primary. The patient initially presented with a painless left cervical mass and was diagnosed through cytology and PET‐CT ...
Jose Ángel Amat‐Sanchez, Ander Paulo Mayor‐Ibarguren, María José Beato‐Merino, Blanca Martínez‐Cabrera, Beatriz Castelo‐Fernández, Francisco Vergara‐Barria, Pedro Herranz‐Pinto   +6 more
wiley   +1 more source

Pembrolizumab combined with anlotinib improves therapeutic efficacy in pulmonary sarcomatoid carcinoma with TMB-H and PD-L1 expression: a case report and literature review [PDF]

, 2023
Shugui Wu, Shanlian Wu, Xiaohong Liao, Chaoming Zhou, Feng Qiu, Chen Wang, Wenjuan Zhong   +6 more
openalex   +1 more source

A Case of Pembrolizumab‐Induced Pityriasis Lichenoides‐Like Eruption Treated Successfully With Dupilumab

JEADV Clinical Practice, EarlyView.
ABSTRACT Immune‐checkpoint inhibitors (ICIs) have revolutionised melanoma treatment but can often cause severe and long‐standing cutaneous immune‐related adverse events (cirAEs). We report a case of refractory pembrolizumab‐induced pityriasis lichenoides (PL)‐like eruption successfully treated with dupilumab, leading to rapid and sustained remission ...
Evangelos Christou, Sharon Edwards, Andrew Affleck   +2 more
wiley   +1 more source

Granulomatous Panniculitis in a Patient Treated With Cemiplimab: Case Report and Literature Review

JEADV Clinical Practice, EarlyView.
ABSTRACT Immune checkpoint inhibitors (ICIs) have become a cornerstone in the treatment of advanced malignancies by enhancing antitumor immunity, but they may also trigger a broad spectrum of immune‐related adverse events (irAEs) involving multiple organs.
B. Lada‐Colunga, J. L. Artola‐Igarza, N. Martinez‐Peña, I. Arevalo‐Ortega, J. Rodriguez‐Blandon, G. Cancho‐Galan, R. Izu‐Belloso   +6 more
wiley   +1 more source

Cost-effectiveness analysis of pembrolizumab versus chemotherapy in advanced non-small cell lung cancer in China based on real-world studies

Journal of Cancer Research and Clinical Oncology
Background Although pembrolizumab has been shown to be effective, its high price has prevented it from being widely used. Especially in the real world, the application situation is still uncertain.
Ning Wan, Chen Yang, Bing Wang, Ya Guo, ZiJian He, YaJuan Lv, LiQing Lu, Ning Yang, WeiBin Xiao, YongBang Chen, Jin Yuan, DanDan Yang, Tao Liu, WenFeng Fang, ZhuoJia Chen, WeiTing Liang   +15 more
doaj   +1 more source